Question

A 60-year-old tests positive for SARS-CoV-2. According to NICE, which group is prioritized for antiviral therapy (e.g. nirmatrelvir/ritonavir) or monoclonal antibodies?

Accepted Answer

Patients at high risk of progression (e.g. immunocompromised)

Answer

All patients with mild COVID-19

Answer

Patients with no comorbidities

Answer

Children under 2 years only

Answer

Routine prophylaxis for contacts

Practice question

A 60-year-old tests positive for SARS-CoV-2. According to NICE, which group is prioritized for antiviral therapy (e.g. nirmatrelvir/ritonavir) or monoclonal antibodies?